News

Naturally occurring microRNA molecules (miRNA) hold the potential to be a new treatment for pulmonary artery disease. A group at Sookmyung University and Yale University led by Professor Kim Jong-min investigated the causes of pulmonary arterial hypertension and discovered new molecular mechanism contributing to the disease. “Our research is…

Chloe Temtchine More support for pulmonary hypertension (PH) is expected to pour in next week during the Pulmonary Hypertension Association‘s (PHA) 2nd Annual O2 Breathe Gala. This year, one of the gala’s honored guests is YouTube sensation and singer-songwriter, Chloe Temtchine, who is…

A pair of nurses from the Stanford University Medical Center are set to conduct a live webinar on much-needed public awareness of clinical research — the most crucial and intensive phase in product and treatment development before achieving marketing approval and finally benefiting consumers and patients everywhere.

At the Max Planck Institute for Heart and Lung Research in Bad Nauheim and Giessen University, a team of scientists under the leadership of Dr. Soni Savai Pullamsetti is uncovering potential reasons why pulmonary arteries become narrowed and lead to pulmonary hypertension. Recent experiments, highlighted in a…

The U.K.’s Chancellor of the Exchequer, George Osborne, has announced that the University of Sheffield will be awarded £7.5 million to expand development of its world-leading clinical lung imaging research — technology that may lead to significant advances in treating a wide range of pulmonary disease, including Pulmonary Hypertension.

To date, twelve therapies have been approved to treat pulmonary arterial hypertension (PAH). Of these, three were approved last year, indicating significant progress in understanding and treating PAH. These advancements were greatly needed, as according to the recent publication of “Pulmonary Arterial Hypertension: Progress and Challenges in…

The Pulmonary Hypertension Association (PHA) has launched a new campaign to raise attention about pulmonary hypertension (PH), called PHAware. The main purpose of the campaign is to reach the general public, news media, and potential donors in order to expand their exposure, both nationally and internationally. One of the…

A new study entitled “Rho-kinase Mediates Right Ventricular Systolic Dysfunction in Rats with Chronic Neonatal Pulmonary Hypertension” published in the October issue of American Journal of Respiratory Cell and Molecular Biology reports that Rho-kinase activity is critical to systolic dysfunction in murine models…

A 2011 study entitled, “Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study” identified the fact that prevalence of heart failure with preserved ejection fraction is increasing in the patient population, and that patient prognosis worsens among those…

Exercise and fitness are two health factors that invariably affect prognoses for most chronic, progressive diseases. Given the stress and immobility that come as a result of illness, maintaining fitness to the best of the patient’s ability is generally a best practice for maximizing quality of life and lifespan.

November has been designated Pulmonary Hypertension Awareness Month by the Pulmonary Hypertension Association, and the organization is already planning on initiatives throughout the month and beyond to help support research, fundraising, advocacy, and awareness about pulmonary hypertension (PH). PH Awareness Month, which will be hosted by the association, will include activities…

ProMetic Life Sciences Inc. is currently preparing an Orphan Drug Designation (ODD) request for the company’s novel Idiopathic Pulmonary Fibrosis (IPF) drug PBI-4050 to the Food and Drug Administration (FDA). According to the company, an external panel of IPF world experts strongly recommend that PBI-4050 be granted…